Participated · Seed · Aug 2026

STRGY AI develops StrategyOS, an AI-powered platform designed to connect daily work to strategic priorities, flag execution drift early and automate board-ready reporting. The product targets Chiefs of Staff, Heads of Strategy and COOs at mid-market companies across Europe. STRGY reports early customer adoption among consumer brands and private equity-backed companies, and says additional enterprise deployments are in progress. The company plans near-term commercial expansion, deeper enterprise relationships and further product launches later this year. Financially, STRGY has secured €1M in angel funding with backing from private investors across the UK, Norway, Switzerland and Finland, plus equity participation from Innovestor's Angel CoFund and non-dilutive support from Business Finland. The founding team includes Samuli Bäck, Anton Skarp, Oskari Listomaa and Niko Savander.

Participated · Equity · Aug 2026

Maculaser develops a temperature-controlled, non-damaging retinal laser therapy intended to treat age-related macular degeneration and other retinal diseases. The company plans to use the new funding to advance the therapy into clinical studies. Its stated aim is to enable earlier disease control to prevent irreversible retinal damage. The financing includes both equity from investors and non-dilutive R&D support from Business Finland. Investors in the latest round include ZEISS Ventures, M2care, Innovestor, Metsola Ventures and other existing shareholders. Since founding, Maculaser has raised a total of EUR 7.6 million.

Led · Seed · Jul 2026

Cornea Sense develops next-generation ophthalmic diagnostic technology originating from Aalto University. The company is advancing its academic research toward a human-compatible research prototype and plans to de-risk key technical and clinical development milestones. Its immediate use of funds is to generate the data, expertise, and validation necessary to progress toward a globally scalable ophthalmic diagnostic product. Cornea Sense secured a €1.1M+ pre-seed financing package combining private angel investment and a Business Finland R&D grant. The company is based in Espoo, Finland and is leveraging Aalto's spinout ecosystem as it moves toward clinical validation.

Participated · Equity · Jun 2026

Aplagon is developing APAC, a first-in-class therapeutic that mimics mast cell–derived heparin proteoglycans to localize antithrombotic and anti-inflammatory activity to sites of vascular injury. APAC is intended for in-hospital use and can be administered locally or by IV infusion, with lead clinical programmes targeting prevention of arteriovenous fistula (AVF) maturation failure in end-stage kidney disease and treatment of chronic limb threatening ischemia (CLTI). The company has dosed more than 70 participants to date with no significant safety concerns reported and recently dosed the first patient in its Phase 2a HEALING trial for PAOD/CLTI. Aplagon has filed a CTA with the EMA and is using its recent EUR 4.8 million financing to expand Phase 2 development in Europe for AVF. The company has raised over EUR 20 million to date through equity and non-dilutive funding from Nordic investors. Aplagon is headquartered in Helsinki, Finland.

Led · Seed · Jun 2026

Tangently builds a live financial model that automatically updates P&L, balance sheet, and cash flow daily by integrating a company's accounting system, CRM, and payments. An AI assistant answers financial questions directly from a company's real data, covering metrics like runway, burn rate, cash position, and pipeline conversion. The product is aimed at growing companies that currently rely on manual spreadsheets and delayed month-end reports, enabling faster decision-making without requiring a CFO. Tangently emphasized removing manual reporting and providing a real-time view of finances. The company offers demos and immediate signup for prospective customers.